Atara Biotherapeutics (ATRA) Stock Forecast, Price Target & Predictions
ATRA Stock Forecast
Atara Biotherapeutics stock forecast is as follows: an average price target of $14.00 (represents a 22.81% upside from ATRA’s last price of $11.40) and a rating consensus of 'Sell', based on 1 wall street analysts offering a 1-year stock forecast.
ATRA Price Target
The average price target for Atara Biotherapeutics (ATRA) is $14.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $10.00. This represents a potential 22.81% upside from ATRA's last price of $11.40.
ATRA Analyst Ratings
According to 1 Wall Street analysts, Atara Biotherapeutics's rating consensus is 'Sell'. The analyst rating breakdown for ATRA stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 0 'Hold' (0.00%), 1 'Sell' (100.00%), and 0 'Strong Sell' (0.00%).
Atara Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 13, 2024 | Benjamin Burnett | Stifel Nicolaus | $10.00 | $7.58 | 31.93% | -12.28% |
| Aug 16, 2024 | Salim Syed | Mizuho Securities | $18.00 | $6.83 | 163.54% | 57.89% |
| Aug 09, 2022 | Goldman Sachs | $3.00 | $3.87 | -22.48% | -73.68% | |
| May 24, 2022 | Goldman Sachs | $4.00 | $4.85 | -17.53% | -64.91% |
The latest Atara Biotherapeutics stock forecast, released on Nov 13, 2024 by Benjamin Burnett from Stifel Nicolaus, set a price target of $10.00, which represents a 31.93% increase from the stock price at the time of the forecast ($7.58), and a -12.28% decrease from ATRA last price ($11.40).
Atara Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $10.00 | $14.00 |
| Last Closing Price | $11.40 | $11.40 | $11.40 |
| Upside/Downside | -100.00% | -12.28% | 22.81% |
In the current month, the average price target of Atara Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Atara Biotherapeutics's last price of $11.40. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 09, 2022 | Goldman Sachs | Sell | Sell | Hold |
| May 24, 2022 | Goldman Sachs | Sell | Sell | Hold |
Atara Biotherapeutics's last stock rating was published by Goldman Sachs on Aug 09, 2022. The company gave ATRA a "Sell" rating, the same as its previous rate.
Atara Biotherapeutics Financial Forecast
Atara Biotherapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $4.25M | $2.14M | $957.00K | $1.23M | $221.00K | $4.46M | $51.58M | $7.31M | $7.55M | $5.37M | $3.87M | $3.55M | - | - |
| Avg Forecast | $14.00M | $18.50M | $17.00M | $40.00M | $25.50M | $28.66M | $37.09M | $24.69M | $2.56M | $5.09M | $4.36M | $32.01M | $34.01M | $5.13M | $6.84M | $5.79M | $31.38M | $4.55M | $4.95M | $2.05M | $15.00M | $1.05B |
| High Forecast | $21.44M | $28.33M | $26.03M | $65.01M | $50.61M | $43.88M | $37.09M | $24.69M | $3.02M | $7.79M | $6.67M | $49.01M | $52.07M | $5.13M | $6.84M | $5.79M | $31.38M | $4.55M | $4.95M | $2.05M | $15.00M | $1.26B |
| Low Forecast | $5.63M | $7.43M | $6.83M | $14.99M | $389.27K | $11.52M | $37.09M | $24.69M | $2.09M | $2.05M | $1.75M | $12.86M | $13.66M | $5.13M | $6.84M | $5.79M | $31.38M | $4.55M | $4.95M | $2.05M | $15.00M | $838.10M |
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | 1.66% | 0.42% | 0.22% | 0.04% | 0.01% | 0.87% | 7.54% | 1.26% | 0.24% | 1.18% | 0.78% | 1.73% | - | - |
Atara Biotherapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $24.69M, with a low forecast of $24.69M, and a high forecast of $24.69M. ATRA's average Quarter revenue forecast represents a 480.68% increase compared to the company's last Quarter revenue of $4.25M (Dec 23).
Atara Biotherapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | $-52.07M | $-69.61M | $-71.41M | $-75.02M | $-75.54M | $-83.25M | $-80.93M | $-86.63M | $-93.40M | $-82.50M | $-81.68M | $-76.02M | $-81.70M | $-9.31M |
| Avg Forecast | $-2.80M | $-3.70M | $-3.40M | $-8.00M | $-5.10M | $-5.73M | $-7.42M | $-84.01M | $-512.40K | $-1.02M | $-871.80K | $-89.85M | $-60.82M | $-1.03M | $-1.37M | $-96.10M | $-6.27M | $-909.36K | $-989.35K | $-81.08M | $-3.00M | $-9.73M |
| High Forecast | $-1.13M | $-1.49M | $-1.37M | $-3.00M | $-77.85K | $-2.30M | $-7.42M | $-67.21M | $-418.29K | $-409.05K | $-350.33K | $-71.88M | $-48.65M | $-1.03M | $-1.37M | $-76.88M | $-6.27M | $-909.36K | $-989.35K | $-64.86M | $-3.00M | $-7.78M |
| Low Forecast | $-4.29M | $-5.67M | $-5.21M | $-13.00M | $-10.12M | $-8.78M | $-7.42M | $-100.81M | $-604.42K | $-1.56M | $-1.33M | $-107.82M | $-72.98M | $-1.03M | $-1.37M | $-115.32M | $-6.27M | $-909.36K | $-989.35K | $-97.29M | $-3.00M | $-11.67M |
| Surprise % | - | - | - | - | - | - | - | - | 101.62% | 68.39% | 81.92% | 0.83% | 1.24% | 81.09% | 59.18% | 0.90% | 14.88% | 90.72% | 82.56% | 0.94% | 27.23% | 0.96% |
undefined analysts predict ATRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Atara Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Atara Biotherapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 |
| Net Income | - | - | - | - | - | - | - | - | $-60.45M | $-69.80M | $-71.11M | $-74.77M | $-74.57M | $-84.09M | $18.47M | $-87.99M | $-93.35M | $-84.66M | $-83.79M | $-78.33M | $-81.31M | $-9.16M |
| Avg Forecast | $-22.10M | $-15.16M | $-15.98M | $5.00M | $-14.88M | $-14.09M | $-16.71M | $-85.67M | $-83.06M | $-116.24M | $-122.48M | $-91.62M | $-62.50M | $-1.14B | $-1.22B | $-97.99M | $-1.07B | $-1.39B | $-1.34B | $-83.44M | $-1.15B | $-9.58M |
| High Forecast | $-4.91M | $-3.37M | $-3.55M | $105.36M | $-6.36M | $-3.13M | $-3.72M | $-68.54M | $-81.70M | $-25.85M | $-27.24M | $-73.30M | $-50.00M | $-1.14B | $-1.22B | $-78.40M | $-1.07B | $-1.39B | $-1.34B | $-66.76M | $-1.15B | $-7.66M |
| Low Forecast | $-37.36M | $-25.62M | $-27.01M | $-95.35M | $-25.17M | $-23.82M | $-28.25M | $-102.80M | $-84.42M | $-196.50M | $-207.04M | $-109.95M | $-75.00M | $-1.14B | $-1.22B | $-117.59M | $-1.07B | $-1.39B | $-1.34B | $-100.13M | $-1.15B | $-11.49M |
| Surprise % | - | - | - | - | - | - | - | - | 0.73% | 0.60% | 0.58% | 0.82% | 1.19% | 0.07% | -0.02% | 0.90% | 0.09% | 0.06% | 0.06% | 0.94% | 0.07% | 0.96% |
Atara Biotherapeutics's average Quarter net income forecast for Sep 22 is $-1.14B, with a range of $-1.14B to $-1.14B. ATRA's average Quarter net income forecast represents a -6300.30% decrease compared to the company's last Quarter net income of $18.47M (Jun 22).
Atara Biotherapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 |
| SG&A | - | - | - | - | - | - | - | - | $10.39M | $12.25M | $13.34M | $13.87M | $13.24M | $18.92M | $18.81M | $20.57M | $21.82M | $19.85M | $19.40M | $17.74M | $16.14M | $3.54M |
| Avg Forecast | $35.86M | $47.39M | $43.55M | $102.47M | $65.32M | $73.42M | $95.02M | $20.00M | $6.56M | $13.04M | $11.17M | $21.39M | $14.61M | $13.15M | $17.52M | $14.83M | $80.37M | $11.65M | $12.67M | $5.26M | $38.42M | $3.71M |
| High Forecast | $54.91M | $72.56M | $66.68M | $166.53M | $129.63M | $112.41M | $95.02M | $24.00M | $7.74M | $19.96M | $17.10M | $25.67M | $17.53M | $13.15M | $17.52M | $14.83M | $80.37M | $11.65M | $12.67M | $5.26M | $38.42M | $4.45M |
| Low Forecast | $14.41M | $19.04M | $17.50M | $38.41M | $997.19K | $29.50M | $95.02M | $16.00M | $5.36M | $5.24M | $4.49M | $17.11M | $11.69M | $13.15M | $17.52M | $14.83M | $80.37M | $11.65M | $12.67M | $5.26M | $38.42M | $2.96M |
| Surprise % | - | - | - | - | - | - | - | - | 1.58% | 0.94% | 1.19% | 0.65% | 0.91% | 1.44% | 1.07% | 1.39% | 0.27% | 1.70% | 1.53% | 3.37% | 0.42% | 0.96% |
Atara Biotherapeutics's average Quarter SG&A projection for Mar 24 is $20.00M, based on 2 Wall Street analysts, with a range of $16.00M to $24.00M. The forecast indicates a 92.55% rise compared to ATRA last annual SG&A of $10.39M (Dec 23).
Atara Biotherapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Mar 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 13 |
| EPS | - | - | - | - | - | - | - | - | $-0.56 | $-0.66 | $-0.68 | $-0.72 | $-0.72 | $-0.82 | $0.18 | $-0.87 | $-0.96 | $-0.90 | $-0.91 | $-0.86 | $-0.95 | $-0.42 |
| Avg Forecast | $-2.96 | $-2.03 | $-2.14 | $0.67 | $-1.99 | $-1.89 | $-2.24 | $-6.42 | $-11.13 | $-15.57 | $-16.40 | $-9.27 | $-12.99 | $-18.64 | $-19.90 | $-23.30 | $-17.35 | $-22.55 | $-21.82 | $-22.53 | $-18.66 | $-0.46 |
| High Forecast | $-0.66 | $-0.45 | $-0.48 | $14.11 | $-0.85 | $-0.42 | $-0.50 | $-1.43 | $-10.94 | $-3.46 | $-3.65 | $-2.06 | $-2.89 | $-18.64 | $-19.90 | $-23.30 | $-17.35 | $-22.55 | $-21.82 | $-22.53 | $-18.66 | $-0.37 |
| Low Forecast | $-5.00 | $-3.43 | $-3.62 | $-12.77 | $-3.37 | $-3.19 | $-3.78 | $-10.85 | $-11.31 | $-26.32 | $-27.73 | $-15.66 | $-21.97 | $-18.64 | $-19.90 | $-23.30 | $-17.35 | $-22.55 | $-21.82 | $-22.53 | $-18.66 | $-0.55 |
| Surprise % | - | - | - | - | - | - | - | - | 0.05% | 0.04% | 0.04% | 0.08% | 0.06% | 0.04% | -0.01% | 0.04% | 0.06% | 0.04% | 0.04% | 0.04% | 0.05% | 0.91% |
According to 1 Wall Street analysts, Atara Biotherapeutics's projected average Quarter EPS for Sep 22 is $-18.64, with a low estimate of $-18.64 and a high estimate of $-18.64. This represents a -10454.58% decrease compared to ATRA previous annual EPS of $0.18 (Jun 22).
Atara Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ALLO | Allogene Therapeutics | $2.07 | $29.00 | 1300.97% | Buy |
| KPTI | Karyopharm Therapeutics | $0.67 | $7.33 | 994.03% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| ITOS | iTeos Therapeutics | $7.69 | $33.50 | 335.63% | Buy |
| HRTX | Heron Therapeutics | $1.65 | $7.00 | 324.24% | Buy |
| SANA | Sana Bio | $1.91 | $8.00 | 318.85% | Buy |
| TCRX | TScan Therapeutics | $2.97 | $12.00 | 304.04% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| FATE | Fate Therapeutics | $1.88 | $5.00 | 165.96% | Buy |
| BTAI | BioXcel Therapeutics | $0.39 | $1.00 | 156.41% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| RCUS | Arcus Biosciences | $16.08 | $31.71 | 97.20% | Buy |
| CRBU | Caribou Biosciences | $1.94 | $3.00 | 54.64% | Buy |
| HOOK | HOOKIPA Pharma | $2.13 | $3.00 | 40.85% | Buy |
| ATRA | Atara Biotherapeutics | $10.35 | $14.00 | 35.27% | Sell |